GSA Capital Partners’s Matinas BioPharma MTNB Stock Holding History

GSA Capital Partners’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-992	Closed	-$967K	–	1657
2021 Q3	$967K	Sell	992 -1,254	-56%	-$812K	0.1%	323
2021 Q2	$1.31M	Buy	+2,246	New	+$1.45M	0.15%	150
2020 Q3	–	Sell	-26	Closed	-$15K	–	1337
2020 Q2	$15K	Buy	+26	New	+$15K	0.01%	563

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $67.3M AUM 9.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

GSA Capital Partners's MTNB Position: Q4 2021 in Review

GSA Capital Partners sold out of Matinas BioPharma (MTNB) in Q4 2021, closing a stake of 992 shares — an estimated $967K sold.

GSA Capital Partners first reported a position in MTNB in Q2 2020 and held it in 3 quarters. The position peaked at $1.31M in Q2 2021. 64 funds tracked by Wall St. Rank hold MTNB as of Q4 2021.

GSA Capital Partners reported no remaining Matinas BioPharma position as of Q4 2021 after selling out during the quarter.
GSA Capital Partners sold 992 Matinas BioPharma shares in Q4 2021, an estimated $967K.
GSA Capital Partners first reported a position in Matinas BioPharma in Q2 2020 and held it in 3 quarters.
GSA Capital Partners's Matinas BioPharma position peaked at $1.31M in Q2 2021.
64 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.